A 63-year-old man with type 2 diabetes, established coronary artery disease and an eGFR of 55 mL/min/1.73 m² has HbA1c 7.8% on maximally tolerated met...

Question

A 63-year-old man with type 2 diabetes, established coronary artery disease and an eGFR of 55 mL/min/1.73 m² has HbA1c 7.8% on maximally tolerated metformin. According to Diabetes Canada, which class of agent should be prioritised next for cardiovascular and renal benefit?

Accepted Answer

Sodium-glucose cotransporter-2 (SGLT2) inhibitor or GLP-1 receptor agonist with proven cardiovascular benefit

Answer

Dipeptidyl peptidase-4 (DPP-4) inhibitor

Answer

Thiazolidinedione

Answer

Short-acting sulfonylurea

Answer

Basal insulin only

ca-mccqe1 MCQ (SBA): Type 2 diabetes with ASCVD

A 63-year-old man with type 2 diabetes, established coronary artery disease and an eGFR of 55 mL/min/1.73 m² has HbA1c 7.8% on maximally tolerated metformin. According to Diabetes Canada, which class of agent should be prioritised next for cardiovascular and renal benefit?